An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

ClinicalTrials.gov ID: NCT07720284

Public ClinicalTrials.gov record NCT07720284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

Study identification

NCT ID: NCT07720284
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 915 participants

Conditions and interventions

Conditions

High-risk Muscle Invasive Urothelial Carcinoma

Interventions

Dato-DXd Drug
Rilvegostomig Drug
Durvalumab Drug
Nivolumab Drug
Pembrolizumab Drug
Enfortumab vedotin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2026
Primary completion: Sep 10, 2030
Completion: Nov 22, 2032
Last update posted: Jul 21, 2026

2026 – 2032

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Hot Springs	Arkansas	71913	Not yet recruiting
Research Site	Little Rock	Arkansas	72205	Not yet recruiting
Research Site	Little Rock	Arkansas	72211	Not yet recruiting
Research Site	San Francisco	California	94143	Not yet recruiting
Research Site	Chicago	Illinois	60637	Withdrawn
Research Site	Boston	Massachusetts	02215	Not yet recruiting
Research Site	Kansas City	Missouri	64132	Not yet recruiting
Research Site	Lincoln	Nebraska	68506	Not yet recruiting
Research Site	Omaha	Nebraska	68130	Not yet recruiting
Research Site	Albany	New York	12208	Not yet recruiting
Research Site	New York	New York	10065	Not yet recruiting
Research Site	Cleveland	Ohio	44195	Not yet recruiting
Research Site	Myrtle Beach	South Carolina	29572	Not yet recruiting
Research Site	Nashville	Tennessee	37203	Not yet recruiting
Research Site	Dallas	Texas	75235	Not yet recruiting
Research Site	Falls Church	Virginia	22042	Not yet recruiting
Research Site	Seattle	Washington	98109	Not yet recruiting
Research Site	Tacoma	Washington	98405	Not yet recruiting
Research Site	Milwaukee	Wisconsin	53226	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07720284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 21, 2026 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07720284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →